Pending Projects

Fecal Microbiota Transplant for C. difficile Infection in Solid Organ Transplant Recipients (FMT)

The FMT trial (pending NIH U01) will test a novel intervention, fecal microbiota transplant, for treatment of C. difficile infection (CDI) in solid organ transplant recipients as compared to the standard of care oral vancomycin in reducing recurrence of CDI in a randomized, multi-center, double-blind, double-dummy controlled trial.

Principal Investigator DCC: Nasia Safdar, MD, University of Wisconsin-Madison
Co-Investigator, DCC Director: KyungMann Kim, PhD, University of Wisconsin-Madison
Target Enrollment: 158

The FMT Data Coordinating Center (DCC) will be led by Professor Kim. He will provide expertise and support for the FMT trial much as in the INVESTED trial in partnership with the Frontier Science Foundation for data management, quality control and quality assurance, and IT support.


A Randomized, Double-blind Trial of Oral Fecal Microbiota Transplantation versus Placebo for the Eradication of Vancomycin-resistant Enterococci Colonization from the Gut (VRE-FMT)

The VRE-FMT trial (pending NIH U01) will test a novel intervention, fecal microbiota transplant (FMT) in oral encapsulation, for eradication of vacomycin-resistant enterococci (VRE) colonization in asymptomatic VRE gut colonized patients in a randomized, double-blind, placebo-controlled trial.

Principal Investigator DCC: Nasia Safdar, MD, University of Wisconsin-Madison
Co-Investigator, DCC Director: KyungMann Kim, PhD, University of Wisconsin-Madison
Target Enrollment: 90

The VRE-FMT Data Coordinating Center (DCC) will be led by Professor Kim. He will provide expertise and support for the VRE-FMT trial with limited involvement in data management which will be done using REDCap.

Contact Us

KyungMann Kim, PhD
DCC Principal Investigator
kyungmann.kim@wisc.edu
608-265-6380

Kelly Miller, BS, CCRC
DCC Research Administrator
kamiller@biostat.wisc.edu
608-262-8141